Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 6/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.34 |
| ▸ | PRKCA | P17252 | 2/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25757498 | 0.94 | S1PR4 (0.36) | S1PR1S1PR3S1PR5S1PR4ACHE | |
| SCHEMBL25758657 | 0.93 | S1PR1 (0.42) | S1PR1S1PR3S1PR5S1PR4PRKCD | |
| SCHEMBL25757496 | 0.90 | S1PR1 (0.40) | S1PR1S1PR3S1PR5S1PR4ACHE | |
| SCHEMBL25247165 | 0.88 | S1PR1 (0.40) | S1PR1S1PR3S1PR5S1PR4ACHE | |
| SCHEMBL25757510 | 0.88 | S1PR1 (0.40) | S1PR1S1PR3S1PR5S1PR4ACHE | |
| SCHEMBL25246953 | 0.88 | S1PR1 (0.40) | S1PR1S1PR3S1PR5S1PR4ACHE | |
| SCHEMBL25760423 | 0.87 | S1PR5 (0.38) | S1PR1S1PR3S1PR5S1PR4PRKCD | |
| SCHEMBL25758803 | 0.83 | S1PR1 (0.43) | S1PR1S1PR3S1PR5S1PR4PRKCD | |
| SCHEMBL25761396 | 0.82 | S1PR1 (0.41) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL25757501 | 0.81 | S1PR1 (0.38) | S1PR1S1PR3S1PR5S1PR4PRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044728-A1 | PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044723-A1 | ENGINEERED RETRONS AND METHODS OF USE | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024020346-A2 | GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023240261-A1 | NUCLEOBASE EDITING SYSTEM AND METHOD OF USING SAME FOR MODIFYING NUCLEIC ACID SEQUENCES | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773061-B2 | Cyclic lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | S1PR1 817/4885S1PR3 573/4885S1PR5 1066/4885 |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | S1PR1 817/4885S1PR3 573/4885S1PR5 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.